Clinical trials: Early Onset Preeclampsia
Preeclampsia
Alterations in the Plasma Proteome of Early-Onset Severe Preeclampsia
The hypothesis of this study is that many plasma proteins are altered in concentration and structure in preeclampsia and the elucidation of these alterations will add to the poorly understood pathophysiology of preeclampsia.
- Trial name
- NCT00719654
- Where
- United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Pre-Eclampsia
Metformin and Esomeprazole in Treatment of Early Onset Preeclampsia
Preeclampsia is globally responsible for tens of thousands of maternal and neonatal deaths each year. Currently, there are no medical therapies to halt disease progression and expectant management and delivery remain the mainstay…
- Trial name
- NCT03717701
- Testing
- metformin, esomeprazole
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Aswan University Hospital
Pre-Eclampsia, Early Onset Preeclampsia
Early Onset Preeclampsia and Nectin-4
Early-onset Preeclampsia (PE) is a pregnancy disorder which may present with adverse pregnancy outcomes. Nectin-4 is an adhesion molecule mainly expressed in placenta.
- Conditions
- Pre-Eclampsia, Early Onset Preeclampsia, Oxidative Stress, Immunologic Diseases in Pregnancy
- Trial name
- NCT05098691
- Testing
- serum marker levels
- Where
- Turkey (Türkiye)
- Volunteers
- 84 people
- Sponsor
- Hatice Akkaya
Preeclampsia
KW-3357 Study in Patients With Early Onset Severe Preeclampsia
The purpose of this study is to evaluate the efficacy of intravenous KW-3357 in patients with early-onset severe preeclampsia by comparing the prolongation days of pregnancy with that of placebo.
- Trial name
- NCT04182373
- Testing
- Antithrombin gamma, physiological saline
- Where
- 63 sites in Japan
- Volunteers
- 181 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Preeclampsia
Screening for Preeclampsia With Various Markers in Low-risk Pregnancy Populations
For the prediction of late-onset preeclampsia (PE) in low risk women, the investigators established a cut-off value for sFlt-1/PlGF ratio and evaluated the combination models of Elecys, second trimester uterine artery (UtA)…
- Trial name
- NCT01649128
- Volunteers
- 262 people
- Sponsor
- CHA University
Severe Preeclampsia
Algorithm-Based Timing of Delivery Using the sFlt-1/PlGF Ratio in Early-Onset Severe Preeclampsia. (MAP 2 Study : Management Based on Angiogenic Markers in Preeclampsia 2 Study )
Preeclampsia is a serious pregnancy complication caused by abnormal placental development and function. It can lead to high blood pressure and damage to organs such as the liver, kidneys, brain, or cardiovascular system.
- Trial name
- MAP 2 (NCT07665112)
- Testing
- sFlt-1/PlGF ratio-guided management algorithm, Usual Care
- Where
- Spain
- Volunteers
- 386 people
- Sponsor
- Hospital Clinic of Barcelona
Pre-Eclampsia
Continuous Non-invasive Hemodynamic Monitoring in Early-onset Severe Preeclampsia: a Comparison of Echocardiography, Bioreactance, and Finger Cuff Measurements
The purpose of this study is to compare the feasibility and accuracy of two methods of non-invasive hemodynamic assessments - bioreactance as assessed by non-invasive cardiac output monitoring (NICOM; Cheetah Medical) and pulse…
- Trial name
- NCT05299229
- Testing
- Echocardiogrpahy and non-invasive monitoring
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Yale University
Pregnancy
Detecting Early Onset Pre-eclampsia and Use of Placental Growth Factor (PlGF) for Marker of Trisomy 21
This is a study for the evaluation of the benefits of 1 st Trimester risk markers in detecting Early Onset Pre-eclampsia and the use of the Placental Growth factor(PIGF) as a potential marker for Trisomy 21 and other…
- Trial name
- PlGF (NCT01387776)
- Where
- Canada
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Clinique Ovo
Preeclampsia (PE), Hypertension ,Pregnancy
Dipyridamole for Early-Onset Preeclampsia: A Pilot Study of Feasibility, Pharmacokinetics, and Biological Effects
Early-onset preeclampsia (PE), defined as preeclampsia presenting before 34 weeks of gestation, is a severe placental disorder associated with significant maternal and perinatal morbidity.
- Trial name
- NCT07738562
- Testing
- Dipyridamole 75 MG
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Hadassah Medical Organization
Monitoring Blood Pressure, Aspirin Prophylaxis
Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income
The goal of this clinical trial is to learn if a telehealth hypertension group prenatal care program (Centering HER / HGPC-T) can improve blood pressure monitoring and aspirin adherence and help reduce early-onset preeclampsia in…
- Trial name
- NCT07491510
- Testing
- Active Comparator: Behavioral: Experimental: Centering HER (routine prenatal care + 7 doula-led 90-minute virtual group
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Preeclampsia
Molecular Screening Method for Preeclampsia (PREMOM)
Preeclampsia (PE) is a major obstetric complication with short- and long-term consequences for the mother and the fetus. Early screening tools to reduce its mortality and morbidity, as well as to prevent the life-threatening…
- Trial name
- PREMOM (NCT04990141)
- Testing
- Peripheral blood collection in cases group, Peripheral blood collection in control group
- Where
- 15 sites in Spain
- Volunteers
- 9,586 people
- Sponsor
- iPremom
Gestational Hypertension
Relation Between Protein 13 and Gestational Hypertensive Disorder
the attendants of the clinic with a one-missed period (T0) underwent determination of baseline blood pressure (BP) measures and gave blood samples for estimation of levels of placental growth factor (PLGF), soluble fms-like…
- Trial name
- NCT05517512
- Testing
- Estimation of Protein 13
- Where
- Egypt
- Volunteers
- 138 people
- Sponsor
- Benha University
Pre-Eclampsia, Pregnancy Related
Study of Nicotinamide in Early Onset Preeclampsia
Phase II Study of 2.5 gm of nicotinamide, given daily in 3 divided doses, to measure effect on maternal blood pressure in women with early onset preeclampsia and to determine peak and trough levels of nicotinamide.
- Trial name
- NCT03419364
- Testing
- nicotinamide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of North Carolina, Chapel Hill
Fetal Growth Retardation, Preeclampsia
Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler
This is a multicentre, open-label, randomized controlled trial. A total of 340 singleton pregnancies with an EFW ≤10th percentile between 26+0 and 31+6 weeks will be recruited and randomly allocated to either the control or the…
- Conditions
- Fetal Growth Retardation, Preeclampsia, Placenta Diseases
- Trial name
- earlyGRAFD (NCT05284474)
- Testing
- soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF)
- Where
- 27 sites in Spain
- Volunteers
- 340 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Preeclampsia, Pulmonary Edema
Point-of-care Ultrasound Abnormalities in Early Onset Preeclampsia
The study is planned to describe the prevalence and severity of cardiac, lung and optic-nerve sheath diameter (ONSD) ultrasound abnormalities in women with early onset preeclampsia with severe features.
- Conditions
- Preeclampsia, Pulmonary Edema, Cardiac Function
- Trial name
- NCT05662995
- Testing
- Lung ultrasound
- Where
- South Africa
- Volunteers
- 60 people
- Sponsor
- University of Cape Town
Preeclampsia
Molecular Study of the Maternal-fetal Interface in Preeclampsia.
Preeclampsia (PE) is a major obstetric complication with short- and long-term consequences for the mother and the fetus. Early screening tools to reduce its mortality and morbidity, as well as to prevent the life-threatening…
- Trial name
- PREMAFE (NCT06232668)
- Testing
- Maternal-fetal interface biopsy and peripheral blood collection in cases group, Maternal-fetal interface biopsy and peripheral blood collection in control group
- Where
- 4 sites in Spain
- Volunteers
- 2,084 people
- Sponsor
- Carlos Simon Foundation
Preeclampsia
Serum Soluble Endoglin and Matrix Metalloproteinase 14 With Elisa Method in Early/Late-onset Preeclampsia
Objective: Defective placentation and inadequate trophoblastic invasion have an important place in the aetiology of preeclampsia (PrE).
- Trial name
- NCT03932877
- Testing
- MMP-14 and s-ENG levels
- Where
- Turkey (Türkiye)
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Cengiz Gokcek Women's and Children's Hospital
Preeclampsia
Progesterone in Expectantly Managed Early-onset Preeclampsia
Preeclampsia is a disorder of widespread vascular endothelial malfunction and vasospasm that occurs after 20 weeks' gestation and can present as late as 4-6 weeks postpartum
- Trial name
- NCT04077853
- Testing
- 17 Hydroxyprogesterone Capronate
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Assiut University
Pre-eclampsia
Disease Modification in Toxaemia of Pregnancy
Short description of the primary purpose of the protocol intended for the lay public. Include brief statement of study hypothesis Pre-eclampsia (toxemia of pregnancy) is the most cause of death among pregnant women in North…
- Trial name
- NCT00175695
- Testing
- Recombinant human activated protein C or drotrecogin alpha
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Preeclampsia
miRNA-452 in Patients With Preeclampsia and Its Correlation With MMP-9
Preeclampsia is a pregnancy related disease characterized by the new onset of hypertension and proteinuria after 20 weeks of gestation in previously normotensive women.
- Trial name
- NCT03258125
- Testing
- real time PCR (rPCR)
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University